The CGT operating model built in 2017 was never designed for today's multi-modality portfolio. Read the brief, then join the live conversation on June 11.

As CGT programs scale across sites, therapy types, and portfolios, the coordination layer holding them together is starting to fracture.

Join senior operators from across biotech, treatment centres, and supply chain leadership for a discussion on where programs actually fail and what commercially ready organisations are doing differently.

From chain-of-identity and chain-of-custody pressures to fragmented digital infrastructure and governance gaps, this session will explore the operational realities emerging as advanced therapies move beyond the industry’s first-wave operating models.

Co-hosted by Phacilitate and BlueSquared, the discussion brings together leaders working directly across CGT operations, manufacturing, treatment centre coordination, and digital enablement to unpack where friction is increasing and how organisations are adapting before those issues become commercial bottlenecks.

Moderator: Becky Johnson — Global Event Director, Phacilitate 

J. Andrew Case — Head of Supply Chain, Cell & Gene Therapies, Genentech/Roche

Arthur Mallian — Senior Cell Therapy Operations, Bristol-Myers Squibb

Ronit Slotky PhD, MSc, CABP — Director, Cell Therapies Manufacturing Facility, Hackensack University Medical Center

A clearer understanding of where coordination failures actually happen across CGT programs

Insight into why orchestration is becoming a distinct operational discipline in advanced therapies

Practical perspectives from operators managing complexity across sites, modalities, and stakeholder groups

A live view of how the audience scores across key operational maturity domains

Access to BlueSquared’s CGT Digital Orchestration Maturity Assessment, including a personalised 10-page report with maturity radar, gap analysis, and a 30-day action plan

CGT is Getting More Complex. Digital Operations Are Struggling to Keep Up